Are Semaglutide Pills Effective for Weight Loss?

What did the clinical trial find?

The OASIS 4 trial is the key evidence base for oral semaglutide's effectiveness in weight management. It enrolled 307 adults with obesity or overweight plus at least one weight-related condition (none had type 2 diabetes) and ran for 64 weeks, comparing semaglutide tablets against placebo alongside lifestyle guidance. The headline result was an average body-weight reduction of around 13.6% in the active group, versus about 2.4% in the placebo group. Among participants who adhered fully to the treatment protocol, average weight loss reached around 16.6%, though that figure only applies to that subset, not the overall population, so the 13.6% average is the more representative number to hold in mind.

The most common side effects in the trial were gastrointestinal: nausea, vomiting, diarrhoea and constipation occurred in around 74% of participants taking the tablet, compared with 42% on placebo. That sounds stark, but most of these effects were mild-to-moderate and tended to settle as the body adjusted. The dosing schedule is designed partly to manage this, you begin at a low dose and step up slowly, spending at least a month at each level, before reaching the 25mg maintenance dose.

For a fuller breakdown of how these figures compare across different ways of taking semaglutide, the semaglutide tablets effectiveness page sets out the numbers side by side.

How does the pill compare with the weekly injection?

A reasonable question, and one worth answering carefully rather than with a simple verdict. The injection form of Wegovy at 2.4mg produced around 15% average weight loss in the STEP 1 trial over 68 weeks, as reported in the New England Journal of Medicine. The tablet's 13.6% average over 64 weeks is slightly lower, which is broadly in line with what pharmacologists would expect: oral absorption of semaglutide is inherently less consistent than subcutaneous delivery, even with the absorption-enhancing formulation used in the tablet.

That gap matters less for some people than others. If the barrier to treatment is the injection itself (needle anxiety, a dislike of self-injection, or a lifestyle that makes refrigerated storage complicated) then a tablet producing 13.6% average weight loss is a meaningful option, not a consolation prize. There is a common assumption that pills are always weaker than injections for GLP-1 medicines; the real picture is more nuanced. The comparison between the pill and the injection explores this properly if you want to read further.

Who were the semaglutide tablets approved for?

The MHRA licence covers adults with a BMI of 30 or above, or those with a BMI between 27 and 29.9 alongside at least one weight-related health condition, for example, high blood pressure, raised cholesterol, prediabetes or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. The tablets are taken once daily first thing in the morning, on an empty stomach, with a small amount of plain water. You wait at least 30 minutes before eating, drinking anything other than plain water, or taking other oral medicines.

One practical difference from the injection worth noting: no fridge required. Room-temperature storage makes this format genuinely easier to manage if you travel regularly or simply find the fridge logistics of the pen fiddly. The oral semaglutide overview covers storage and administration in more detail, and the MHRA's announcements on semaglutide document the evolving regulatory picture. Because the tablets are a prescription-only medicine, a prescriber reviews your health history before any treatment is considered, BMI alone does not determine suitability.

What about Rybelsus, isn't that also a semaglutide tablet?

Yes, and it is worth clearing this up. Rybelsus contains semaglutide at 3mg, 7mg and 14mg strengths, but it is licensed specifically for type 2 diabetes management, not weight loss. The Wegovy tablet is a distinct formulation at different doses (1.5mg, 4mg, 9mg and 25mg) approved solely for weight management, and our semaglutide pills page explains how these dose strengths work and what sets this format apart from other semaglutide products. They are not interchangeable, and a prescriber would not issue Rybelsus for someone seeking weight-loss treatment. If you have come across information about semaglutide tablets and are unsure which product applies to your situation, the comparison between Rybelsus and Wegovy sets out the distinction plainly. The Wegovy pill overview also covers the licensed indication, the dosing ladder and what to expect from treatment.

If you are considering semaglutide tablets and want to talk through whether they suit your circumstances, our prescribers are available seven days a week. Speak to our prescribers through a free consultation, same-day clinical review, no waiting list.